Knowledge Hub

Rotavirus vaccination saves money and prevents millions of cases, hospitalizations, and deaths

This study provided an updated model of the cost-effectiveness of rotavirus vaccination in children younger than 5 years across 73 countries previously or currently eligible for Gavi support. The researchers found evidence that rotavirus vaccination is still a cost-effective investment in Gavi countries, projected to save approximately $484 million (around $48 million per year) from the government perspective and $878 million (around $90 million per year) from the societal perspective between 2018 and 2027, by preventing 158.6 million cases of rotavirus gastroenteritis, 80.7 million outpatient visits, 7.9 million hospitalizations, 14.7 million Disability-Adjusted Life Years, and nearly 600,000 deaths.

Full Citation:
Debellut F, Clark A, Pecenka C et al.. 2019. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Global Health. 7(12).

Title of Article: Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study

Author(s): Debellut F, Clark A, Pecenka C et al.

Publication Year: 2019

Publication Name: Lancet Global Health

Publication Volume: 7(12)

Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/31708147/

DOI (Digital Object Identifier): 10.1016/S2214-109X(19)30439-5

Topics: Economics & Return on Investment

Disease Vaccines: Diarrhea | Rotavirus

Countries: Global